|1939||Establishment of Koa Kagakukogyo Co., Ltd. Initiation of the manufacturing and sales of nourishing food article.|
|1940||Company name changed to Koa Eiyokagaku Kenkyusho Co., Ltd.|
|1941||Initiation of the manufacturing and sales of drugs for the organ systems of the human body.|
|1943||Capital investment by Tanabe Seiyaku Co., Ltd and a marketing alliance.|
|1946||Company name changed to Nihon Eiyokagaku Co., Ltd.|
|1949||Powdered agar for the detection of bacteria, the first product of the field successfully commercialized in Japan.|
|1950||Commercialization of "SS agar medium" for the detection of dysentery bacillus, etc.|
|1955||Inauguration of the monthly publication "Modern Media".|
|1961||Establishment of Clinical Laboratory Division.
Initiation of R&D of in vitro diagnostics.
|1965||Completion of the first-Stage of construction of the Nogi Plant in Nogi-City, Tochigi.Initiation of production.
Inauguration of the Saburo Kojima Memorial Society.
|1969||Company name Changed to Eiken Chemical Co., Ltd. in recognition of its 30th anniversary.|
|1975||Establishment of the Oji branch in kita-ku, Tokyo.|
|1980||Completion of the new headquarter building in Bunkyo-ku, Tokyo.|
|1984||Completion of the first-stage of construction of the Nasu Plant in Otawara-City, Tochigi.|
|1987||Completion of the second-stage of construction of the Nasu Plant.
Initiation of the production of angiographic contrast mediums.
Commencement of the sales of the angiographic contrast medium "Hexabrix 320".
|1989||Completion of the Immuno-serologic Factory (the 8th Nogi Plant Factory). Initiation of production.|
|1990||Stocks listed in the second section of the Tokyo Stock Exchange.
Establishment of the Ryogoku branch in Sumida-ku, Tokyo.
|1992||Establishment of the Biochemical Research Laboratory in Nogi-machi, Tochigi.|
|1993||Establishment of the Kurozumi Medical Foundation (K M F).
First issuance of unsecured convertible bonds.
|1996||Completion of the new plant for contrast media in Nasu Factory.|
|1997||Commencement of the sales of "Feridex", an MRI enhancement material.|
|1998||Development of novel DNA amplification "LAMP" method and filing of its patent applications.|
|2000||Sales alliance for microbiology test-related products with Becton Dickinson Japan Co., Ltd.
Commencement of the sales of OC-Sensor µ, a fully automated fecal occult blood analyzer.
|2001||Initiation of direct sales of in vitro diagnostics.
Commencement of the sales of Magnescope Syringe for MRI material.
Commencement of the sales of OC-Sensor neo, a fully automated fecal occult blood analyzer.
Establishment of Eiken Logistics Service Co., Ltd. (E L S).
|2002||Stocks listed on the first section of the Tokyo Stock Exchange.
LAMP method patent granted in U.S.A. and Japan.
Commencement of the sales of novel "Loopamp Bovine Embryo Sexing Kit" and its "End Point Turbidimeter".
Commencement of online service of the LAMP Primer design support software.
Sales alliance with Sysmex for automated urine analyzers and test strips for urinalysis in China.
Commencement of the sales of novel "Lumispot ‘Eiken’ HCV Antigen".
|2003||Commencement of the sales of "Loopamp Salmonella Screening Kit", "Loopamp Verotoxin-producing Escherichia
coli Screening Kit", and "Loopamp Verotoxin Typing Kit".
Agreement with FUJIHIRA INDUSTRY on the distribution of Loopamp Bovine Embryo Sexing Kit in China.
Agreement with POLYMEDCO inc. on the sales and purchase of reagents and analyzers for the fecal occult blood test in North American market.
Commencement of the sales of "Loopamp SARS-CoV detection kit".
|2004||Established EIKEN SHANGHAI CO., LTD. in China.
Commencement of the sales of "Loopamp Primer Set for West Nile Virus" as the first primer set.
Commencement of the sales of "Centrifugal machine EC-10" and "Blood collecting set ‘Eiken’ " as devices for mailing medical checkup.
Acquired FDA approval for FOBT reagent and analyzer, which have been available for sale.
|2005||Commencement of the sales of automated urine analyzer "US-1000".
Transition to Company with Committee System.
Collaboration to develop rapid diagnostic test for Tuberculosis with The Foundation for Innovative New Diagnostics (FIND).
Eiken obtained ISO13485:2003 and ISO9001:2000 certification.
Strategic partnership agreement between Eiken and Hitachi High-Technologies Corporation.
|2006||Strategic partnership agreement between Eiken and Otsuka Pharmaceutical Co., Ltd.|
|2007||Tetsuya Teramoto became President and CEO.
Merged EIKEN KIZAI CO., LTD. which was previously a subsidiary.
Establishment of BRAVE CIRCLE Committee. (It became NPO Corporation in 2009.)
|2008||Development of the procedure for ultra rapid extraction method "PURE method" for LAMP
Relocated our headquarter in Taito-ku, Tokyo.
|2009||Establishment of new management vision ‘EIKEN WAY’ and ‘EIKEN ROAD MAP 2009’.|
|2010||Commencement of the sales of various LAMP products. (Detection for H1pdm, Mycoplasma, Legionella, HSV, FulA)
Obtainment of ISO14001 certification.
|2011||Commencement of the sales of “Loopamp MTBC Detection Kit”.
Establishment of Europe office in Amsterdam (the Netherlands).
|2012||Completion of construction of OMC building in Nogi Division.
Disposal of Oji Office.
Closing of the Togane Factory.
Commencement of the sales of "BLEIA-1200", the fully-automatic biochemistry photogenetic immunoassay device.
|2013||Commencement of the sales of three hepatitis screening kits for "BLEIA-1200".|
|2014||Commencement of the sales of "DPS 192iX", the drug sensitivity tests device and "Dry Plate'EIKEN'(192)".
Morifumi Wada became President and CEO.